Response to Office Action

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1957 (Rev 10/2011)

OMB No. 0651-0050 (Exp 09/20/2020)

---

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1957 (Rev 10/2011)

OMB No. 0651-0050 (Exp 09/20/2020)

Response to Office Action

To the Commissioner for Trademarks:

Application serial no. 88517655 KINDLIA(Standard Characters, see http://uspto.report/TM/88517655/mark.png) has been amended as follows:

CLASSIFICATION AND LISTING OF GOODS/SERVICES

Applicant proposes to amend the following class of goods/services in the application:
Current: Class 005 for Pharmaceutical preparations; pharmaceutical preparations used for the treatment of parathyroid, glandular and hormone disorders; pharmaceutical preparations used for the treatment of renal and kidney disorders; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, oncological diseases and disorders, hematological diseases and disorders, tumorous diseases, autoimmune diseases, inflammation, inflammatory diseases and disorders, neurologic diseases and disorders, metabolic diseases and disorders; pharmaceuticals for stimulating the growth of platelets and platelet precursor cells; erythropoiesis stimulating protein; pharmaceuticals for stimulating white blood cell production; pharmaceuticals for modulating the level of calcium in the bloodstream and for the treatment of hyperparathyroidism and hypercalcemia; pharmaceuticals for treating human immune diseases and conditions; pharmaceutical preparations for the treatment of bone disease; and pre-filled syringes containing pharmaceutical preparations for treatment of the aforementioned diseases and disorders and complications associated therewith
Original Filing Basis:
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to use the mark in commerce on or in connection with the identified goods/services in the application. For a collective trademark, collective service mark, or collective membership mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members on or in connection with the identified goods/services/collective membership organization. For a certification mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification standards of the applicant.

Proposed:
Tracked Text Description: Pharmaceutical preparations; Pharmaceutical preparations used for the treatment of parathyroid, glandular and hormone disorders; pharmaceutical preparations used for the treatment of renal and kidney disorders; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, oncological diseases and disorders, hematological diseases and disorders, tumorous diseases, autoimmune diseases, inflammation, inflammatory diseases and disorders, neurologic diseases and disorders, metabolic diseases and disorders; pharmaceuticals for stimulating the growth of platelets and platelet precursor cells; erythropoiesis stimulating protein; pharmaceuticals for stimulating white blood cell production; pharmaceuticals for modulating the level of calcium in the bloodstream and for the treatment of hyperparathyroidism and hypercalcemia; pharmaceuticals for treating human immune diseases and conditions; pharmaceutical preparations for the treatment of bone disease; and pre-filled syringes containing pharmaceutical preparations for treatment of the aforementioned diseases and disorders and complications associated therewithClass 005 for Pharmaceutical preparations used for the treatment of parathyroid, glandular and hormone disorders; pharmaceutical preparations used for the treatment of renal and kidney disorders; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, oncological diseases and disorders, hematological diseases and disorders, tumorous diseases, autoimmune diseases, inflammation, inflammatory diseases and disorders, neurologic diseases and disorders, metabolic diseases and disorders; pharmaceuticals for stimulating the growth of platelets and platelet precursor cells; erythropoiesis stimulating protein; pharmaceuticals for stimulating white blood cell production; pharmaceuticals for modulating the level of calcium in the bloodstream and for the treatment of hyperparathyroidism and hypercalcemia; pharmaceuticals for treating human immune diseases and conditions; pharmaceutical preparations for the treatment of bone disease; and pre-filled syringes containing pharmaceutical preparations for treatment of the aforementioned diseases and disorders and complications associated therewith
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to use the mark in commerce on or in connection with the identified goods/services in the application. For a collective trademark, collective service mark, or collective membership mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members on or in connection with the identified goods/services/collective membership organization. For a certification mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification standards of the applicant.

The applicant's current attorney information: Timothy J. Gaul. Timothy J. Gaul of AMGEN INC., is located at

      TRADEMARK OPERATIONS - MS-28-5A
      ONE AMGEN CENTER DRIVE
      THOUSAND OAKS, California 91320-1799
      US
The docket/reference number is TM-1441-US-2.

The phone number is 805-447-2688.

The email address is tmops@amgen.com

The applicants proposed attorney information: Timothy J. Gaul. Other appointed attorneys are Elsa D. Lemoine, Richard V. Person, Stuart L. Watt. Timothy J. Gaul of Amgen Inc., is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at

      Trademark Operations - MS 28-5-
      One Amgen Center Drive
      Thousand Oaks, California 91320-1799
      United States
The docket/reference number is TM-1441-US-2.

The phone number is 805-447-2688.

The email address is tmops@amgen.com

Timothy J. Gaul submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.
The applicant's current correspondence information: TIMOTHY J. GAUL. TIMOTHY J. GAUL of AMGEN INC., is located at

      TRADEMARK OPERATIONS - MS-28-5A
      ONE AMGEN CENTER DRIVE
      THOUSAND OAKS, California 91320-1799
      US
The docket/reference number is TM-1441-US-2.

The phone number is 805-447-2688.

The email address is tmops@amgen.com

The applicants proposed correspondence information: Timothy J. Gaul. Timothy J. Gaul of Amgen Inc., is located at

      Trademark Operations - MS 28-5-
      One Amgen Center Drive
      Thousand Oaks, California 91320-1799
      United States
The docket/reference number is TM-1441-US-2.

The phone number is 805-447-2688.

The email address is tmops@amgen.com

SIGNATURE(S)
Response Signature
Signature: /Timothy J. Gaul/     Date: 02/05/2020
Signatory's Name: Timothy J. Gaul
Signatory's Position: Attorney of record, California Bar Member

Signatory's Phone Number: 8054472688

The signatory has confirmed that he/she is a U.S.-licensed attorney who is an active member in good standing of the bar of the highest court of a U.S. state (including the District of Columbia and any U.S. Commonwealth or territory); and he/she is currently the owner's/holder's attorney or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another U.S.-licensed attorney not currently associated with his/her company/firm previously represented the owner/holder in this matter: the owner/holder has revoked their power of attorney by a signed revocation or substitute power of attorney with the USPTO; the USPTO has granted that attorney's withdrawal request; the owner/holder has filed a power of attorney appointing him/her in this matter; or the owner's/holder's appointed U.S.-licensed attorney has filed a power of attorney appointing him/her as an associate attorney in this matter.

Mailing Address:    TIMOTHY J. GAUL
   AMGEN INC.
   TRADEMARK OPERATIONS - MS-28-5A
   ONE AMGEN CENTER DRIVE
   THOUSAND OAKS, California 91320-1799
Mailing Address:    Timothy J. Gaul
   Amgen Inc.
   Trademark Operations - MS 28-5-
   One Amgen Center Drive
   Thousand Oaks, California 91320-1799
        
Serial Number: 88517655
Internet Transmission Date: Wed Feb 05 18:46:17 EST 2020
TEAS Stamp: USPTO/ROA-XXX.XXX.XXX.XXX-20200205184617
796942-88517655-7003aa82fa2615b1eb893483
8f1822eb661e434595b4bb624c803fbb5e65f885
59-N/A-N/A-20200205174337328321